Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV
暂无分享,去创建一个
L. Shaw | S. Walker | E. Lhomme | Adrian | Julia Doyle Kathryn Kenny | Cissy Ronan Kityo | Victor Cook George Musiime
[1] E. Maidji,et al. Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction , 2017, PLoS pathogens.
[2] M. Netea,et al. Mortality in children with complicated severe acute malnutrition is related to intestinal and systemic inflammation: an observational cohort study12 , 2016, The American journal of clinical nutrition.
[3] A. d’Arminio Monforte,et al. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy , 2016, AIDS.
[4] S. Moreno,et al. Visceral leishmaniasis as an independent cause of high immune activation, T‐cell senescence, and lack of immune recovery in virologically suppressed HIV‐1‐coinfected patients , 2015, HIV medicine.
[5] M. Lederman,et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. , 2014, The Journal of infectious diseases.
[6] L. Madrid,et al. Microbial translocation and T cell activation are not associated in chronic HIV-infected children , 2014, AIDS.
[7] M. Nakakeeto,et al. Prevalence of Bloodstream Pathogens Is Higher in Neonatal Encephalopathy Cases vs. Controls Using a Novel Panel of Real-Time PCR Assays , 2014, PloS one.
[8] P. Sax,et al. Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 , 2014, Journal of acquired immune deficiency syndromes.
[9] S. Gianella,et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia , 2014, Mucosal Immunology.
[10] N. Klein,et al. Short communication: Evidence that microbial translocation occurs in HIV-infected children in the United Kingdom. , 2013, AIDS research and human retroviruses.
[11] D. Douek,et al. Immune activation and HIV persistence: implications for curative approaches to HIV infection , 2013, Immunological reviews.
[12] C. Rouzioux,et al. The Th17/Treg Ratio, IL-1RA and sCD14 Levels in Primary HIV Infection Predict the T-cell Activation Set Point in the Absence of Systemic Microbial Translocation , 2013, PLoS pathogens.
[13] D. Neau,et al. Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. , 2013, The Journal of infectious diseases.
[14] G. Freeman,et al. Down-Regulation of CTLA-4 by HIV-1 Nef Protein , 2013, PloS one.
[15] W. Borkowsky,et al. Increased Gut Microbial Translocation in HIV-infected Children Persists in Virologic Responders and Virologic Failures After Antiretroviral Therapy , 2012, The Pediatric infectious disease journal.
[16] L. Montaner,et al. Increased Microbial Translocation in ≤180 Days Old Perinatally Human Immunodeficiency Virus-positive Infants as Compared With Human Immunodeficiency Virus-exposed Uninfected Infants of Similar Age , 2011, The Pediatric infectious disease journal.
[17] A. d’Arminio Monforte,et al. Evidence for Polymicrobic Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy , 2011, PloS one.
[18] Handan Wand,et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.
[19] T. Quinn,et al. Is microbial translocation a cause or consequence of HIV disease progression? , 2011, The Journal of infectious diseases.
[20] S. Deeks,et al. HIV infection, inflammation, immunosenescence, and aging. , 2011, Annual review of medicine.
[21] G. Poli,et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. , 2010, The Journal of infectious diseases.
[22] O. Laeyendecker,et al. C-Reactive Protein Levels Increase During HIV-1 Disease Progression in Rakai, Uganda, Despite the Absence of Microbial Translocation , 2010, Journal of acquired immune deficiency syndromes.
[23] M. Wallet,et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy , 2010, AIDS.
[24] B. Clotet,et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART , 2010, AIDS.
[25] P. Klenerman,et al. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells , 2010, AIDS.
[26] R. Kaul,et al. HIV-1 RNA Dysregulates the Natural TLR Response to Subclinical Endotoxemia in Kenyan Female Sex-Workers , 2009, PloS one.
[27] J. Margolick,et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa , 2009, Proceedings of the National Academy of Sciences.
[28] M. Lederman,et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. , 2009, The Journal of infectious diseases.
[29] Lewis H Kuller,et al. Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.
[30] C. Tincati,et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy , 2008, AIDS.
[31] Steven Wolinsky,et al. Microbial Translocation Is Associated with Increased Monocyte Activation and Dementia in AIDS Patients , 2008, PloS one.
[32] C. Giaquinto,et al. Immune reconstitution in human immunodeficiency virus type 1‐infected children with different virological responses to anti‐retroviral therapy , 2007, Clinical and experimental immunology.
[33] J. Brenchley,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.
[34] Jeffrey N. Martin,et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses , 2006, AIDS.
[35] R. Knight,et al. UniFrac: a New Phylogenetic Method for Comparing Microbial Communities , 2005, Applied and Environmental Microbiology.
[36] N. Jones,et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. , 2005, The Journal of infectious diseases.
[37] B. Freedman,et al. Macrophage activation through CCR5‐ and CXCR4‐mediated gp120‐elicited signaling pathways , 2003, Journal of leukocyte biology.
[38] K. Harris,et al. Development of broad-range 16S rDNA PCR for use in the routine diagnostic clinical microbiology service. , 2003, Journal of medical microbiology.
[39] J. Moore,et al. Risk Assessment Models and Contamination Management: Implications for Broad-Range Ribosomal DNA PCR as a Diagnostic Tool in Medical Bacteriology , 2002, Journal of Clinical Microbiology.
[40] J V Giorgi,et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.
[41] C. Estcourt,et al. CD14lowCD16high: A cytokine‐producing monocyte subset which expands during human immunodeficiency virus infection , 1995, European journal of immunology.
[42] J. Mege,et al. Increased interleukin-6 production is associated with disease progression in HIV infection. , 1991, AIDS.
[43] M. Kazatchkine,et al. HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 alpha in vitro. , 1989, AIDS.
[44] A. Walker,et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial , 2016, The Lancet. Infectious diseases.
[45] F. Månsson,et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. , 2010, The Journal of infectious diseases.
[46] Peter Piot,et al. Joint United Nations Program on HIV/AIDS (UNAIDS) , 1997 .